02599nas a2200193   4500008004100000245011600041210006900157260000800226300001200234490000800246520190600254100001702160700001702177700002102194700001702215700002402232700002702256856012202283       2016                        eng d00aEvaluating the anticancer activity and nanoparticulate nature of homeopathic preparations of Terminalia chebula0 aEvaluating the anticancer activity and nanoparticulate nature of  cNOV  a318-3260 v1053 aBackground: Breast cancer is the most common cancer diagnosed among women and is the second leading cause of cancer death. Homeopathic medicines are part of the alternative medicines that are given as a supportive therapy in breast cancer. The objective of this study was to investigate the anticancer activity of commercially available homeopathic preparations of Terminalia chebula (TC) and evaluate their nanoparticulate nature. 
Methods: Mother tincture (MT) and other homeopathic preparations (3X, 6C and 30C) of TC were tested for their effect on the viability of breast cancer (MDAMB231 and MCF7) and non-cancerous (HEK 293) cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell growth assay was performed to analyze the effect of the different potencies on the growth kinetics of breast cancer cells. MT and 6C were evaluated for the presence of nanoparticles by using scanning electron microscopy (SEM) and transmission electron microscopy (TEM). 
Results: MT decreased the viability of breast cancer (MDAMB231 and MCF7) and non-cancerous (HEK 293) cells. However, the other potencies (3X, 6C and 30C) decreased the viability of only breast cancer cells without affecting the viability of the non-cancerous cells. All the potencies, MT, 3X, 6C and 30C, reduced growth kinetics of breast cancer cells, more specifically at 1:10 dilution at 24, 48 and 72 h. Under SEM, MT appeared as a mesh-like structure whereas under TEM, it showed presence of nanoclusters. On the other hand, 6C potency contained 20 nm sized nanoparticles. 
Conclusion: The current study reports the anticancer activity of homeopathic preparations of TC against breast cancer and reveals their nanoparticulate nature. These preliminary results warrant further mechanistic studies at both in vitro and in vivo levels to evaluate the potential of TC as nanomedicine in breast cancer.1 aWani, Kirtee1 aShah, Nilesh1 aPrabhune, Asmita1 aJadhav, Arun1 aRanjekar, Prabhakar1 aKaul-Ghanekar, Ruchika  uhttps://library.ncl.res.in/content/evaluating-anticancer-activity-and-nanoparticulate-nature-homeopathic-preparations00818nas a2200241   4500008004100000022001400041245010700055210006900162260000900231300000800240490000700248653001500255653001300270653002100283653001900304653001600323100002400339700002500363700002200388700002400410700001600434856012600450       2020                        eng d  a1663-981200aPhytochemicals in cancer treatment: from preclinical studies to clinical practice (vol 10, 1614, 2020)0 aPhytochemicals in cancer treatment from preclinical studies to c  cFEB   a1750 v1110aAnticancer10aclinical10amedicinal plants10aphytochemicals10apreclinical1 aChoudhari, Amit, S.1 aMandave, Pallavi, C.1 aDeshpande, Manasi1 aRanjekar, Prabhakar1 aPrakash, Om  uhttps://library.ncl.res.in/content/phytochemicals-cancer-treatment-preclinical-studies-clinical-practice-vol-10-1614-202002459nas a2200253   4500008004100000022001400041245008600055210006900141260000800210300000900218490000700227520166700234653001501901653001301916653002101929653001901950653001601969100002401985700002502009700002202034700002402056700001602080856010902096       2020                        eng d  a1663-981200aPhytochemicals in cancer treatment: from preclinical studies to clinical practice0 aPhytochemicals in cancer treatment from preclinical studies to c  cJAN  a16140 v103 a<p>Cancer is a severe health problem that continues to be a leading cause of death worldwide. Increasing knowledge of the molecular mechanisms underlying cancer progression has led to the development of a vast number of anticancer drugs. However, the use of chemically synthesized drugs has not significantly improved the overall survival rate over the past few decades. As a result, new strategies and novel chemoprevention agents are needed to complement current cancer therapies to improve efficiency. Naturally occurring compounds from plants known as phytochemicals, serve as vital resources for novel drugs and are also sources for cancer therapy. Some typical examples include taxol analogs, vinca alkaloids such as vincristine, vinblastine, and podophyllotoxin analogs. These phytochemicals often act via regulating molecular pathways which are implicated in growth and progression of cancer. The specific mechanisms include increasing antioxidant status, carcinogen inactivation, inhibiting proliferation, induction of cell cycle arrest and apoptosis; and regulation of the immune system. The primary objective of this review is to describe what we know to date of the active compounds in the natural products, along with their pharmacologic action and molecular or specific targets. Recent trends and gaps in phytochemical based anticancer drug discovery are also explored. The authors wish to expand the phytochemical research area not only for their scientific soundness but also for their potential druggability. Hence, the emphasis is given to information about anticancer phytochemicals which are evaluated at preclinical and clinical level.</p>
10aAnticancer10aclinical10amedicinal plants10aphytochemicals10apreclinical1 aChoudhari, Amit, S.1 aMandave, Pallavi, C.1 aDeshpande, Manasi1 aRanjekar, Prabhakar1 aPrakash, Om  uhttps://library.ncl.res.in/content/phytochemicals-cancer-treatment-preclinical-studies-clinical-practice